CD44 and ovarian cancer: analyzed patient-matched primary, metastatic, and recurrent tumor samples from 26 ovarian cancer patients and showed higher CD44 expression in metastatic and relapsed tumor tissues compared to patient-matched primary tumors, while at the same time CD44 knockdown significantly reduced proliferation and invasion capability of ovarian cancer cells in vitro (44).